Clinical trials: Alzheimer Dementia (AD)
Alzheimer Disease, Alzheimer Disease (AD)
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60.
- Conditions
- Alzheimer Disease, Alzheimer Disease (AD), Alzheimers Disease Prevention
- Trial name
- NCT06831812
- Testing
- AV-1959R (Abeta vaccine)
- Where
- Australia
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Nuravax, Inc.
Mild Cognitive Impairment Due to Alzheimer's Disease, Alzheimer's Disease Dementia
A Study to Learn About the Safety of Diranersen (BIIB080) Injections and Whether They Can Improve Symptoms of Participants With Mild Cognitive Impairment Due to Alzheimer's Disease (AD) or Mild AD Dementia Between 50 to 80 Years of Age
In this study, researchers will learn more about a study drug called diranersen (BIIB080). The study will focus on participants with mild cognitive impairment or mild dementia due to AD.
- Trial name
- CELIA (NCT05399888)
- Testing
- Diranersen
- Where
- 138 sites in United States, Australia and 15 more
- Volunteers
- 416 people
- Sponsor
- Biogen
Alzheimer's Disease, Mild Cognitive Impairment
A Phase II Trial of 18F-AV-45 Positron Emission Tomography (PET) Imaging in Healthy Volunteers, Patients With Mild Cognitive Impairment (MCI) and Patients With Alzheimer's Disease (AD)
Evaluate 18F-AV-45 positron emission tomography (PET) imaging for distinguishing healthy control subjects, from subjects with Alzheimer's disease (AD) or Mild cognitive impairment (MCI).
- Trial name
- NCT00702143
- Testing
- florbetapir F 18
- Where
- 15 sites in United States
- Volunteers
- 184 people, healthy volunteers welcome
- Sponsor
- Avid Radiopharmaceuticals